Lite Strategy, Inc. (LITS): Capital Expenditures
$0
Year ended 2025-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $0 | -100.0% | 2025-09-26, From 2024-07-01 |
| 2024-06-30 | $7.0K | -80.0% | 2025-09-26, From 2023-07-01 |
| 2023-06-30 | $35.0K | -92.7% | 2023-09-26, From 2022-07-01 |
| 2022-06-30 | $479.0K | -32.3% | 2023-09-26, From 2021-07-01 |
| 2021-06-30 | $708.0K | -20.8% | 2022-09-08, From 2020-07-01 |
| 2020-06-30 | $894.0K | +312.0% | 2022-09-08, From 2019-07-01 |
| 2019-06-30 | $217.0K | n/a | 2022-05-23, From 2018-07-01 |
| No annual figure between 2017-06-30 and 2019-06-30. | |||
| 2017-06-30 | $51.0K | n/m | 2019-08-28, From 2016-07-01 |
| 2016-06-30 | $4.0K | -73.3% | 2018-08-30, From 2015-07-01 |
| 2015-06-30 | $15.0K | -70.0% | 2017-09-05, From 2014-07-01 |
| 2014-06-30 | $50.0K | +31.6% | 2016-09-06, From 2013-07-01 |
| 2013-06-30 | $38.0K | n/a | 2015-09-02, From 2012-07-01 |
| No annual figure between 2011-06-30 and 2013-06-30. | |||
| 2011-06-30 | $48.0K | n/a | 2012-09-18, From 2010-07-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
| Procyon Corp (PCYN) | 2024-06-30 | $63.9K | -64.5% |
Compare LITS, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗